Kornimate/medical-research-clean huggingface dataset:
efficacy and safety study of combination of ginkgo extract and ginseng extract(yy-162)in children with adhd

Conditions: Mental Disorders

Summary: this study will evaluate clinical efficacy and safety of treatment with yy-162 in children with adhd

this is double-blind, two arms, multi-center, interventional, 8 weeks study starting with yy-162(combination of ginkgo extract and ginseng extract in children with adhd. assessment of efficacy and safety will be performed at the baseline, weeks 2,4, and 8. at the first visit, a full psychiatric history, demographic date and physical examination will be undertaken. throughout the study, the following procedures, documentations and evaluations will performed; k-ars, iowa conner's rating scale , cgi-s/i, ata, children's color trails test and stroop test, intelligence test(from kedi-wisc) and adverse event reporting.

Eligibility criteria:
inclusion criteria: * male and female subjects aged from 6 to 12 * subjects must meet dsm-iv criteria for adhd based-on the k-schedule for affective disorder and schizophrenia(k-sads-pl-k) interview * subjects signed a written consent form voluntarily. * patient 's assent to participate in the study and written informed consent form signed by one of the parents, parent surrogates, or legal guardian. * subjects who can keep visit schedule and whose parent/ parent surrogates or legal guardian can willingly complete assessments defined in the study protocol * subjects/parents, parent surrogates or legal guardian who can understand the participation of the study and voluntarily withdraw from the study at any time exclusion criteria: * subjects who have difficulty swallowing tablet. * subjects who have known allergy to plant extracts. * subjects who meet dsm-iv diagnostic criteria for current major depressive disorder or anxiety disorder requiring drug therapy. * subjects who have any history of bipolar disorder, psychotic disorder, and substance use disorder, have been diagnosed with a pervasive developmental disorder, organic brain disease and seizure disorder. * subjects who have significant suicidal ideation. * subjects with mental retardation * subjects with tourette's syndrome requiring drug therapy. * subjects who have been administrated methylphenidate or atomoxetine within recent 3 months and ginkgo extract or ginseng extract within recent 1 month. * subjects who currently have a significant medical conditions (e.g. diseases of cardiovascular, hepatic, renal, respiratory, glaucoma). * subjects who have abnormalities in the ecg or show clinically significant abnormalities of laboratory results, including serum chemistries and hematology. * subjects who are currently taking alpha-2 adrenergic receptor agonist, antidepressant, antipsychotic, benzodiazepines, modafinil,anticonvulsant * subjects who receive psychosocial treatment during the drug trial. * subjects who are not able to swallow the study drug.

Keywords: adhd(attention deficit hyperactivity disorder)
in vitro organoid drug sensitivity-guided treatment for metastatic pancreatic and gastric cancer

Conditions: Pancreatic Cancer; Gastric Cancer

Summary: the goal of this study is to evaluate the consistency between in vitro tumor organoid drug sensitivity and the therapeutic efficacy of in vivo drug treatment. participants are required to provide one of fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) for the purpose of culturing tumor organoids.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 75 years old. 2. metastatic pancreatic cancer with progression after second-line or higher treatment, metastatic gastric cancer with progression after third-line or higher treatment, or metastatic pancreatic or gastric cancer patients who cannot tolerate standard treatment regimens. 3. able to provide fresh tumor tissue specimens for organoid culture, including: ascites, pleural effusion, tumor biopsy tissues, tumor surgical specimens, etc. 4. eastern cooperative oncology group (ecog) performance status (ps) score of 0-2. 5. adequate organ function, including the following: * bone marrow: absolute neutrophil count (anc) in peripheral blood ≥ 1.5 x 10\^9/l, platelets ≥ 100 x 10\^9/l, hemoglobin ≥ 80 g/l. * liver: total bilirubin ≤ 1.5 times the upper limit of normal (uln), aspartate aminotransferase (ast or sgot) and alanine aminotransferase (alt or sgpt) ≤ 3 times uln. if liver metastases are present, aspartate aminotransferase (ast or sgot) and alanine aminotransferase (alt or sgpt) ≤ 5 times uln. * kidney: creatinine clearance ≥ 45 ml/min (using the standard cockcroft-gault formula) or ≤ 1.5 times uln. 6. at least one measurable or evaluable lesion. 7. for women: must be sterilized, postmenopausal, or using highly effective contraception during treatment and for 3 months after treatment; must not be pregnant or breastfeeding during treatment. 8. patient compliance and geographic proximity to ensure adequate follow-up. exclusion criteria: 1. any unstable systemic disease (including systemic active infections requiring treatment, liver disease, kidney disease, or metabolic diseases, acute cerebral infarction or cerebral hemorrhage, etc.) that, in the investigator's judgment, may impair patient safety or the patient's ability to complete the study due to severe comorbidities. 2. significant cardiovascular events: congestive heart failure \> nyha class 2; unstable angina, active coronary artery disease (cad) (myocardial infarction more than 1 year before the study is allowed); severe arrhythmias requiring treatment (use of beta-blockers or digoxin is allowed) or uncontrolled hypertension, etc. 3. significant history of neurological or psychiatric disorders, including epilepsy, dementia, etc. 4. pregnant or breastfeeding women; those of childbearing potential who are unwilling or unable to use effective contraception. 5. other situations that the investigator judges may affect the conduct and determination of the clinical research results.

Keywords: pancreatic cancer gastric cancer organoid drug sensitivity
effects of cop exercise and hiit on vascular health in young overweight females

Conditions: Vascular Diseases

Summary: the goal of this study is to determine the effects of high-intensity interval training and crossover point exercise training on vascular health in young overweight women.

in recent years, improving cardiovascular health through exercise has become a popular research question, however, it is not clear which intensity and modes of exercise bring more benefits. crossover point(cop) intensity has great medical potential as a personalized exercise intensity that is based on substrate utilization mode, especially in overweight and obese people.on the other hand, several studies have demonstrated that hiit is an effective method in improving vascular endothelial dysfunction. during our study, we evaluated the vascular health changes in young overweight women who received either cop exercise or hiit exercise for 10 weeks.

Eligibility criteria:
inclusion criteria: 1. female, 18-30 years old 2. body mass index (bmi) \< 28 kg/m2 and ≥ 24 kg/m2 3. no exercise habit, and no recent new exercise plan 4. no contraindications to exercise exclusion criteria: 1. participates had an orthopedic or other condition that limited participation in daily exercise 2. participates had a history of myocardial infarction, stroke, diabetes mellitus, chronic respiratory disease or cancer 3. participates had smoking or alcohol behavior
trial of paclitaxel, gemcitabine and cisplatin in patients with relapsing germ cell cancer

Conditions: Testicular Cancer

Summary: study objectives: primary objective * the primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with bep. secondary objectives * overall survival * progression free survival * response rates (recist) * duration of response * to investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with bep

not relevant

Eligibility criteria:
inclusion criteria: * histologically confirmed germ cell tumor (seminoma or non-seminoma) with measurable metastatic disease either by radiography (at a site which has previously not been irradiated) or elevation of alpha fetoprotein (afp) and/or elevation of beta-human chorionic gonadotropin (beta-hcg); * patient previously treated with standard bep (3 or 4 cycles) with relapse 1 months or more after favorable response on previous chemotherapy (cr or pr) * male * age greater than or equal to 18 years; * performance status 0,1,2 or 3 * wbc \> 3000 mill/l, anc \> 1500 mill/l, platelet count \> 100.000 mill/l; serum bilirubin \< 1.5 x the upper limit of normal; * adequate renal function (glomerular filtration rate (gfr) \>60 ml/min). gfr will be assessed by direct measurement (edta clearance or creatinine clearance) * signed informed consent; exclusion criteria: * uncontrolled active severe clinical infection (ctc grade 3 or 4). * serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator), including expected difficulty of follow-up related to mental disorders. * grade 2 or greater peripheral neuropathy according to the ctc, version 3.0. * second malignancy other than basal or squamous cell skin cancer.

Keywords: relapse
clinical and radiographic assessment after surgical treatment of anterior shoulder dislocation

Conditions: Anterior Shoulder Dislocation; Bone Defects; Shoulder Instability

Summary: the purpose of this study is to evaluate the clinical and radiographic results after surgical treatment with implant-free allograft in the treatment of anterior shoulder dislocation and to assess the safety of the surgery.

patients will be informed about the study and potential risks. all patients giving written informed consent will undergo a screening visit to assess the eligibility criteria. patients who meet the eligibility requirements will perform a pre-treatment visit in order to assess their healthy state. also, patients will undergo to the radiographic visit (rx and tx) as request by clinical practice. all the patients will be treated with arthrotomy mini-open technique with bone allograft at the site of the shoulder lesion. after surgery all the patients will be followed up to 24 months through clinical and radiographic visits.

Eligibility criteria:
inclusion criteria: * antero.inferior shoulder instability with bone loss exclusion criteria: * patients incapable of understanding or wanting; * patients suffering from: rheumatic diseases, diabetes, infectious processes, congenital ligament laxity, epilepsy, severe osteoporosis.

Keywords: implant-free shoulder instability bone grafting shoulder instability glenoid allograft
lung fluid and peripheral blood neutrophil il-5 surface receptor in children with asthma

Conditions: Asthma

Summary: the pattern of lower airway inflammation in asthma is heterogeneous, but in many patients, the polymorphonuclear neutrophil (pmn) is the predominant granulocyte infiltrating the airspaces. although it is known to have an important function in innate immune defense, the role of the pmn in asthma has not been well elucidated. in work in progress, the investigators have identified the receptor for il-5 on the surface of bronchoalveolar lavage (bal) pmns in a subset of children with severe, treatment-resistant asthma, a characteristic that is not found in peripheral blood neutrophils. while the function of this il-5 receptor has yet to be determined, preliminary evidence strongly supports a mechanism linking neutrophilic with type 2 inflammation in the lower airways of children with asthma, a discovery that has exciting potential to modify the treatment of asthma. the primary objective of this observational cross-sectional study is to test the overall hypothesis that therapeutic intervention directed against the il-5r on lung pmns will decrease inflammation and improve clinical outcomes in patients with poorly controlled asthma. the secondary study objective is to demonstrate that il-5r expression on lung-infiltrating pmns is functional, will activate known il-5r-induced signaling pathways, and will lead to enhanced pmn pro-inflammatory activity including increased pmn recruitment, prolonged survival, degranulation, and release of reactive oxygen species.


Eligibility criteria:
inclusion criteria: * ages 0-17 * treatment-resistant, refractory respiratory symptoms * scheduled for a clinical diagnostic bronchoscopy exclusion criteria: * known lower respiratory tract infection within 60 days of scheduled bronchoscopy * systemic disorders involving the heart, respiratory system, cns, renal, and endocrine systems
men1703 (sel24) in participants with acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the purpose of the clinical trial is to identify the maximum tolerated dose of men1703 and to further investigate its safety profile in participants with acute myeloid leukemia (aml).

phase i/ii, open-label, multi-center, dose escalation study to estimate the maximum tolerated dose of men1703 in participants with acute myeloid leukemia. the clinical trial will investigate the safety profile and anti-leukemic activity of men1703 in participants with aml and that have no standard therapeutic options available. the clinical trial encompasses 2 parts: * part 1: ascending dose levels - the main purpose of this part of the clinical trial is to determine the highest dose of men1703 considered to be well tolerated. * part 2: expansion cohort - the main purpose of this part of the clinical trial is to assess the safety and anti-leukemia activity of men1703 given at the highest tolerated dose in participant with relapsed/refractory acute myeloid leukemia, either all comers as well as harboring isocitrate dehydrogenase (idh1/idh2) mutations. participants participating to the clinical trial will take the study drug as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.

Eligibility criteria:
inclusion criteria: * participants with diagnosis of aml, all comers or bearing idh1 or idh2 mutation (completed) * participant has no standard therapeutic options available and has either relapsed aml unsuitable for intensive chemotherapy, with no standard therapeutic options and/or not eligible for any approved targeted therapy or primary refractory aml unsuitable for intensive chemotherapy, with no standard therapeutic options and/or not eligible for any approved targeted therapy exclusion criteria: * anti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy or investigational drugs) received within 14 days or 5 half-lives for targeted therapies (whichever is shorter) before first dose of study drug (to be supplemented)

Keywords: aml relapsed/refractory acute myeloid leukemia idh
prp for treatment of peyronie's disease

Conditions: Peyronie Disease; Sexual Dysfunction, Physiological; Sexual Dysfunction Male; Genital Diseases, Male

Summary: the purpose of this study is to learn about the effects of platelet-rich plasma (prp) injection in men with peyronie's disease (pyd).


Eligibility criteria:
inclusion criteria: 1. be male 2. be 18 to 75 years of age (inclusive). 3. be able to provide written informed consent 4. have a diagnosis of pd with evidence of active or stable disease as determined by the investigator 5. penile curvature deformity of \>30° to \<120° 6. agree to comply with all study related tests/procedures. exclusion criteria: 1. previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting. 2. previous intralesional injection therapy (such as xiaflex) for pd. 3. previous history of priapism or penile fracture 4. pd characterized by a ventral plaque 5. severe erectile dysfunction as characterized with an international index of erectile function (iief) score ≤ 16 6. actively on anticoagulation during time frame of injections (aspirin 81 mg will be eligible for therapy) 7. hour-glass deformity 8. unwilling to participate 9. medically unfit for sexual intercourse as deemed by the principal investigator 10. patients scheduled to undergo an elective medical procedure during the investigation timeframe that will interfere with autologous prp injection therapy. 11. have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.

Keywords: pd pyd prp
diagnosis test of real-time polymerase chain reaction (rt-pcr) for pulmonary tuberculosis

Conditions: Tuberculosis; Pulmonary

Summary: background: pulmonary tuberculosis remains the leading cause of morbidity and mortality in thailand. the microbiological detection of tb is important because of early and correct diagnosis, drug resistance testing and ensures that the effective treatment can be achieved and in a timely manner. mycobacterial culture is the gold standard diagnostic test. currently, a real-time polymerase chain reaction (rt-pcr) assay, such as allplex™ mtb/mdre detection, seegene is commonly used. objective: to evaluate the diagnosis value of the real-time multiplex pcr by using allplex™ mtb/mdre detection kit to detect mtb from sputum specimens with a gold standard tb culture.

a retrospective study design of adult patients (\&gt; 15 years) with suspected pulmonary m. tuberculosis infection was conducted from january 2023 until october 2023, at khon kaen hospital. sample size was 101 cases. sensitivity, specificity, accuracy, negative predictive value (npv), and positive predictive value (ppv) of allplex™ mtb/mdre detection, each with its respective 95% confidence interval (95% ci) were analysed with compared to mtb culture as the gold standard.

Eligibility criteria:
inclusion criteria: * clinical suspected pulmonary m. tuberculosis infection * aged 15 years and older exclusion criteria: * children under 15 years old * non-tuberculous mycobacteria (ntm) detection

Keywords: pulmonary tuberculosis real-time pcr diagnosis test
autologous transplantation of mesenchymal stem cells (mscs) and scaffold in full-thickness articular cartilage

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to investigate the efficacy and safety of autologous transplantation of bone marrow mesenchymal stem cells (mscs) mixed with collagen i scaffold in patient with knee cartilage defects and osteoarthritis

articular cartilage defects have a weak potential for self-repair because of the reduced mitotic capacity of chondrocytes in vivo. because some patients with articular cartilage defects may progress to osteoarthritis, such defects need to be repaired even though their exact natural course remains obscure. traditional methods for repair, such as micro fracture, perforations, abrasion arthroplasty, have not produced consistent satisfactory long term clinical results. transplantation of autologous bone marrow mscs expanded in culture would be a promising approach in the repair of articular cartilage defects in human osteoarthritic knees. this method is clinically straightforward to perform because autologous cells can be readily harvested and expanded in culture without losing their capacity to differentiate into chondrocytes. the purpose of this study was to evaluate the clinical results obtained with autologous mscs expanded in culture for the treatment of full-thickness chondral defects in human knee.

Eligibility criteria:
inclusion criteria: * age 45 to 60, inclusive * normal axial alignment * stable knee-previous ligament reconstruction, if stable * intact articular cartilage in posterior meniscal weight-bearing zone * ability to understand and willingness tosign consent from * o.c.d or oa calgran classification ii,iii exclusion criteria: * pregnant or lactating * inflammatory arthritis * oral steriod, methotrexate * unable to follow post-operative exercise regimen or return for evaluations

Keywords: knee cartilage diseases
smart home-based technology to promote functional mobility among individuals with parkinson's disease

Conditions: Parkinson Disease

Summary: many patients with parkinson's disease suffer of gait disorder termed as "freezing of gait" (fog). non-pharmacological approach such as applying external cues is effective in mitigating fog events. the aim of this study is to test the feasibility and patients satisfaction from a first stage of technology development, designed to deliver automatically external cues to the patients in their homes.

people with parkinson's disease (pwp) may experience severe difficulties in mobility that negatively affect their function and quality of life. freezing of gait, (fog) is a brief and sudden inability to initiate walking or move forward, despite an intention to walk. such episodes are often observed when pwp attempt to turn, cross a narrow space or negotiate obstacles. rehabilitation interventions for fog represent the most effective non-pharmacological approach to maintain functional independence and reduce the risk of falls. a key approach is the provision of external cues, defined as sensory stimuli, which facilitate gait initiation and continuation. these external cues are suggested to bypass the dysfunctional movement pathways in the basal ganglia and therefore, are considered effective in alleviating fog. cueing can be applied by different modalities; the most common are visual (e.g. spaced lines on the floor) and auditory (e.g. rhythmic metronome beats). the term smart-home refers to a range of technologies that are designed for and deployed in individual residences, and are equipped with non-invasive, environmental, and physiological sensors. the concept of a "health smart-home" is a variation of smart-home with a focus on assistive technologies to enable the independence and wellness of residents, including the elderly and patients in supervised residences. in this study, the investigators will be testing the first phase of developing a smart-home technology designed for patients coping with pd to use in their homes and aims to improve gait and assist in prevention of fog. the aims of this exploratory study are to evaluate the 1) practical feasibility of the technology, 2) patient satisfaction and 3) the effect of the technology on gait. the device was developed by selfit medical© and included application of light stripes (visual cues) and metronome beats (auditory cues) that are individually adjusted to the participant walking parameters.

Eligibility criteria:
inclusion criteria: * patient is able to walk independently * the patient report on daily episodes of fog as indicated by question #2 in the new fog questionnaire ("how frequently do you experience freezing episodes?"). * score\>18 on the telephone version of the mini-mental state examination (tmmse) * intact hearing and vision by self-declaration exclusion criteria • the patient suffer of any neurological condition other than parkinson's disease.

Keywords: parkinson's disease freezing of gait smart-home